Lynx1 Capital Management LP 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 09:21 am Sale | 2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE | Lynx1 Capital Management LP | 1,997,006 4.200% | -216,172 (-9.77%) | Filing |
| 2023-01-23 4:28 pm Purchase | 2023-01-13 | 13G | Kinnate Biopharma Inc. KNTE | Lynx1 Capital Management LP | 2,213,178 5.000% | 2,213,178 (New Position) | Filing |